Is AstraZeneca a Dividend Stock to Watch?

Before you go, we thought you'd like these...
Before you go close icon

Shares of pharma giant AstraZeneca (NYS: AZN) rose slightly today -- despite reporting mediocre third quarter earnings. Year-over-year revenue dropped, and sales took a hit after some of the company's high profile drugs lost patent protection this year.

In the following video, health care analysts Max Macaluso and David Williamson discuss these results, AstraZeneca's new CEO, and one of AstraZeneca's potential acquisition targets -- Amarin  (NAS: AMRN) .

 


The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air,  the success of its new triglyceride lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with our new premium research report. Click here now to keep reading.

 

The article Is AstraZeneca a Dividend Stock to Watch? originally appeared on Fool.com.

Max Macaluso has no positions in the stocks mentioned above. David Williamson owns shares of Amarin and Pfizer, but he holds no other position in any company mentioned. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners